NCT02715011View on ClinicalTrials.gov

Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML)

PHASE1CompletedINTERVENTIONAL
Enrollment

62

Participants

Timeline

Start Date

June 1, 2016

Primary Completion Date

March 26, 2021

Study Completion Date

March 26, 2021

Conditions
Leukemia, Myeloid, Acute
Interventions
DRUG

JNJ-63709178

Participants will receive JNJ-63709178 in Part 1 and Part 2.

Trial Locations (10)

Unknown

Detroit

New York

Charlotte

Philadelphia

Pittsburgh

Nashville

Houston

Barcelona

Madrid

Seville

All Listed Sponsors
lead

Janssen Research & Development, LLC

INDUSTRY

NCT02715011 - Dose Escalation Study of JNJ-63709178, a Humanized CD123 x CD3 DuoBody in Participants With Relapsed or Refractory Acute Myeloid Leukemia (AML) | Biotech Hunter | Biotech Hunter